Genentech, a member of the Roche Group, has entered into a generative AI collaboration for drug discovery with U.S. semiconductor giant NVIDIA.
The collaboration will involve utilizing NVIDIA DGX Cloud, an AI supercomputing platform, to accelerate Genentech’s drug discovery models. The focus is on optimizing Genentech’s drug discovery AI models in its 'lab in a loop' framework, with the ultimate goal of improving R&D success rates. NVIDIA will help Genentech optimize its framework by accelerating training and inference of Genentech’s drug discovery models.
Genentech says it plans to use NVIDIA's BioNeMo, a platform that enables biotech companies to customize models at scale.
"Collaborating with NVIDIA, and introducing generative AI, has the power to turbocharge the discovery and design of therapeutics that will improve the lives of patients across the world,” said Aviv Regev, executive VP and head of Genentech Research & Early Development.
This isn't the first AI-focused development deal for Genentech. Back in 2020, the drugmaker entered an AI-driven, multi-target drug discovery partnership with California-based Genesis Therapeutics.